FocalTherics (NASDAQ:FOCL) Earns Buy Rating from HC Wainwright

FocalTherics (NASDAQ:FOCL)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 139.23% from the stock’s current price.

Several other research firms have also recently issued reports on FOCL. Piper Sandler reiterated a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a research report on Friday, August 14th. Mizuho set a $15.00 price target on FocalTherics and gave the company an “outperform” rating in a research note on Friday, July 17th. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of FocalTherics in a report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, FocalTherics presently has an average rating of “Hold” and a consensus price target of $7.75.

FocalTherics Trading Up 1.2%

NASDAQ:FOCL opened at $4.18 on Tuesday. FocalTherics has a 12-month low of $1.30 and a 12-month high of $6.40. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.38 and a current ratio of 1.60. The company has a 50 day moving average of $5.34. The firm has a market capitalization of $156.88 million, a price-to-earnings ratio of -4.06 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The company had revenue of $13.20 million for the quarter. FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%. Research analysts forecast that FocalTherics will post -0.78 EPS for the current fiscal year.

Insider Activity

In other FocalTherics news, Director Fran Schulz bought 10,000 shares of the business’s stock in a transaction on Friday, August 14th. The stock was bought at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the transaction, the director owned 15,100 shares in the company, valued at approximately $71,725. The trade was a 196.08% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ryan Rhodes purchased 21,000 shares of FocalTherics stock in a transaction on Friday, August 14th. The stock was acquired at an average cost of $4.75 per share, for a total transaction of $99,750.00. Following the acquisition, the chief executive officer directly owned 626,649 shares of the company’s stock, valued at approximately $2,976,582.75. This represents a 3.47% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 116,000 shares of company stock worth $551,000 in the last three months. Company insiders own 10.10% of the company’s stock.

Institutional Investors Weigh In On FocalTherics

Large investors have recently bought and sold shares of the stock. SmartHarvest Portfolios LLC acquired a new position in shares of FocalTherics in the first quarter worth $38,000. Lido Advisors LLC acquired a new stake in shares of FocalTherics during the first quarter valued at $40,000. Kovack Advisors Inc. purchased a new stake in FocalTherics during the 4th quarter worth about $53,000. Leonteq Securities AG purchased a new stake in FocalTherics during the 4th quarter worth about $313,000. Finally, Flax Pond Capital LLC acquired a new position in FocalTherics in the 4th quarter valued at about $2,623,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.